scholarly journals Medical care utilization and mortality in sickle cell disease: A population-based study

2005 ◽  
Vol 80 (4) ◽  
pp. 262-270 ◽  
Author(s):  
Sadhna M. Shankar ◽  
Patrick G. Arbogast ◽  
Ed Mitchel ◽  
William O. Cooper ◽  
Winfred C. Wang ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Medical Care ◽  
Sickle Cell ◽  
Population Based ◽  
Care Utilization ◽  
Cell Disease ◽  
Population Based Study ◽  
Medical Care Utilization

Treatment and Outcomes of Hepatocellular Carcinoma in Patients with Sickle Cell Disease: A Population-Based study in the U.S.

HPB ◽  
2021 ◽  
Author(s):  
Arianna Barbetta ◽  
Cameron Goldbeck ◽  
Angelina Lim ◽  
Sean P. Martin ◽  
Jeffrey A. Kahn ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Population Based ◽  
Cell Disease ◽  
Population Based Study ◽  
The U.S

scholarly journals Mortality in Sickle Cell Disease -- A Population Based Study in an Aboriginal Community in the Gudalur Valley, Tamil Nadu, India

2020 ◽  
Author(s):  
VEENA SHESHADRI ◽  
Shabeer PK ◽  
Vatshalan Santhirapalan ◽  
Anusha Jayaraman ◽  
Lakshmanan Krishnamurti ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Tamil Nadu ◽  
Population Based ◽  
Cell Disease ◽  
Population Based Study ◽  
Aboriginal Community

Mortality in sickle cell disease: A population‐based study in an aboriginal community in the Gudalur Valley, Nilgiris, Tamil Nadu, India

2020 ◽  
Author(s):  
Veena Sheshadri ◽  
Pathayakandi Shabeer ◽  
Vatshalan Santhirapala ◽  
Anusha Jayaram ◽  
Lakshmanan Krishnamurti ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Tamil Nadu ◽  
Population Based ◽  
Cell Disease ◽  
Population Based Study ◽  
Aboriginal Community

scholarly journals Bleeding in patients with sickle cell disease: a population-based study

2020 ◽  
Vol 4 (5) ◽  
pp. 793-802 ◽  
Author(s):  
Nisha Hariharan ◽  
Ann Brunson ◽  
Anjlee Mahajan ◽  
Theresa H. M. Keegan ◽  
Ted Wun
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Cumulative Incidence ◽  
Bleeding Event ◽  
Population Based ◽  
Cell Disease ◽  
Gi Tract ◽  
Bleeding Events ◽  
Population Based Study ◽  
Upper Gi

Abstract Bleeding is a known complication of sickle cell disease (SCD) and includes hemorrhagic stroke, hematuria, and vitreous hemorrhage. However, the incidence of bleeding events in patients with SCD has not been well described. We present a retrospective, population-based study examining the cumulative incidence of bleeding in 6423 patients with SCD from 1991 to 2014. We also studied risk factors associated with bleeding and the effects of bleeding on mortality, using Cox proportional hazards regression models. We used California emergency department and hospitalization databases to identify patients with SCD with intracranial hemorrhage, gastrointestinal (GI) bleeding, hemophthalmos, gross hematuria, epistaxis, menorrhagia, and other bleeding events. The cumulative incidence of any first bleeding event at age 40 years was 21% (95% confidence interval [CI], 19.8%-22.3%), increasing with age to 41% by age 60 years (95% CI, 38.8%-43.1%). The majority of bleeding events were GI (41.6%), particularly from the upper GI tract. A higher bleeding risk was associated with increased frequency of hospitalization (hazard ratio [HR], 2.16; 95% CI, 1.93-2.42), venous thromboembolism 180 days before bleeding event (HR, 4.24; 95% CI, 2.86-6.28), osteonecrosis of the femoral head (HR, 1.25; 95% CI, 1.08-1.46), and ischemic stroke (HR, 1.65; 95% CI, 1.20-2.26). Bleeding was also associated with a twofold increased risk for death (HR, 2.09; 95% CI, 1.82-2.41) adjusted for other SCD-related complications. Our novel finding of a high incidence of bleeding in patients with SCD, particularly from the upper GI tract, suggests that patients with SCD may be predisposed to bleeding, with possible etiologies including increased use of nonsteroidal anti-inflammatory drugs, mucosal infarction from vascular occlusion by sickled red blood cells, and increased stress ulceration from frequent hospitalization.

scholarly journals Impact of COVID 19 Pandemic on Health Care Utilization for Patients with Sickle Cell Disease - a Specialty Treatment Center Experience

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 4955-4955
Author(s):  
Akshat Jain ◽  
Amie Patel ◽  
Udochukwo Oyoyo ◽  
Seth Wiafe
Keyword(s):  
Health Care ◽  
Sickle Cell Disease ◽  
Length Of Stay ◽  
Health Care Utilization ◽  
Medical Care ◽  
Sickle Cell ◽  
Inpatient Care ◽  
Care Utilization ◽  
Cell Disease ◽  
Time Points

Abstract Introduction: Starting in March 2020, the coronavirus 19 disease (COVID-19) pandemic affected the United States (US) health care system. Many individuals were afraid to seek medical care due to fear of obtaining COVID-19; therefore, there was a high frequency of adults forgoing medical care. Chronic conditions including diabetes, COPD, mental health, and HTN outcomes worsened due to decrease in routine care during the pandemic. Sickle cell disease (SCD) is a chronic blood disorder that causes numerous complications including but not limited to vaso-occlusive crisis, strokes, and chronic kidney disease. Individuals who have routine follow up with a hematologist have been shown to have decreased hospitalizations, ER visits, length of stay, and opiate usage. The Inland Empire region of Southern California is one of the densest hot spots for patient's living with sickle cell disease in terms of disease burden and health care utilization. Therefore, we evaluated how the COVID-19 pandemic affected health care utilizations with individuals with SCD in this area. Methods: A retrospective analysis of the health care utilization in the inpatient setting was performed at three time points in line with the C.D.C. COVID pandemic declaration (Pre COVID: September 2019 to February 2020, Intra COVID 1: March 2020 to Sept 2020, Intra COVID 2: October 2020 to February 2021). Primary endpoints included emergency room visits, inpatient admissions, and length of stay, blood product utilization, and opioid utilization. Secondary endpoints and analyses included pediatric vs. adult health care utilization disparity and outcomes. Descriptive analysis was done by calculating frequency and percentages for categorical variables and mean and standard deviation for continuous variables. Results: Shown in Result TABLE attached .Patients seeking inpatient care for scheduled procedure's/ transfusion were excluded from this analysis. Patients with SCD diagnoses of acute SCD crises (pan crisis /chest syndrome / COVID infection / Pneumonia) were included in assessment. Absolute number of patients per ED visit, patient per Inpatient admission frequency has been shown in more detail in the bar chart in Figure and will be presented in the oral presentation along with detailed data analysis box plots and charts. Discussion: Fewer patients' sought timely care for acute SCD event leading to fewer but prolonged hospitalizations, a trend seen in our adult and pediatric patient's across the board during intra COVID 1 and 2 time points, likely due to the fear of contracting COVID infection at an acute health care setting in a declared pandemic . Similarly, we found there were less unique sickle cell patients using the ER for both pediatric and adult patients during the pandemic. There was a decrease in the amount of hospital admission related to sickle cell disease, which was similar to results published in the United Kingdom. More sickle cell vaso-occlusive crisis were being managed at home, likely due to avoidance of COVID exposures at health care facilities, likely thus leading to certain individuals having more severe crisis as shown by increased LOS in our adult population. Additionally, only a few individuals with likely more severe crisis needed more RBC transfusions. The general trend for different patients requiring RBCs and IV opiates decreased during the pandemic. Due to more people foregoing medical care especially in the minority populations who had restrictions to access to healthcare, there was an overall decrease in inpatient healthcare utilization in sickle cell population during the pandemic. Additionally care disparities in outcome of pediatric and adult SCD patients were highlighted by our study. Pediatric patients commonly cared at a center of excellence by the dedicated team of sickle cell stakeholders, seemed to do well overall as compared to adult SCD patients who notoriously have has inequitable access to comprehensive Sickle Cell care globally. Infrastructure around better outpatient support, care optimization with sickle cell disease modifying agents and timely access to inpatient care even in a pandemic, that is ongoing could be strategies to reduce stress on the health care systems and better utilization of scarce resources in current times of surge from an International health care crisis such as the SAR CoV2 pandemic. Figure 1 Figure 1. Disclosures Jain: GBT: Consultancy; CSL Behring: Consultancy, Speakers Bureau; Takeda: Consultancy, Speakers Bureau; Octapharma: Consultancy; Blue Bird Bio: Consultancy.

Sign in / Sign up

Export Citation Format

Share Document